Avian and reptile derived polynucleotide encoding a polypeptide having heparanase activity

Abstract

Avian and reptile derived heparanase.

What is claimed is:  
     
         1 . A recombinant protein comprising a polypeptide being at least 75% similar to SEQ ID NO:4, as determined using the BESTFIT software of the Wisconsin sequence analysis package, utilizing the Smith and Waterman algorithm, where gap weight equals 8 and length weight equals 2, average match equals 2.912 and average mismatch equals −2.003, said polypeptide having heparanase catalytic activity or said polypeptide is cleavable by a protease so as to have said heparanase catalytic activity.  
     
     
         2 . A recombinant protein comprising a polypeptide encoded by a nucleic acid including a polynucleotide sequence being at lest 65% identical to SEQ ID NO:10 or a portion thereof as determined using the BESTFIT software of the Wisconsin sequence analysis package, utilizing the Smith and Waterman algorithm, where gap weight equals 50, length weight equals 3, average match equals 10 and average mismatch equals −9, said polypeptide having heparanase catalytic activity or said polypeptide is cleavable by a protease so as to have said heparanase catalytic activity.  
     
     
         3 . A recombinant protein comprising a polypeptide being encoded by a nucleic acid as set forth in SEQ ID NO:10.  
     
     
         4 . A recombinant protein comprising a polypeptide encoded by a polynucleotide sequence being hybridizable with SEQ ID NO:10 under hybridization conditions of hybridization solution containing 10% dextrane sulfate, 1 M NaCl, 1% SDS and 5×10 6  cpm  32 p labeled probe, at 65° C., with a final wash solution of 1× SSC and 0.1% SDS and final wash at 65° C., said polypeptide having heparanase catalytic activity or said polypeptide is cleavable by a protease so as to have said heparanase catalytic activity.  
     
     
         5 . A pharmaceutical composition comprising, as an active ingredient, the recombinant protein of  claim 1  and a pharmaceutically acceptable carrier.  
     
     
         6 . A pharmaceutical composition comprising, as an active ingredient, the recombinant protein of  claim 2  and a pharmaceutically acceptable carrier.  
     
     
         7 . A pharmaceutical composition comprising, as an active ingredient, the recombinant protein of  claim 3  and a pharmaceutically acceptable carrier.  
     
     
         8 . A pharmaceutical composition comprising, as an active ingredient, the recombinant protein of  claim 4  and a pharmaceutically acceptable carrier.